Moderna Inc to Discuss Updates on Respiratory Syncytial Virus (RSV) Vaccine Program Call Transcript
Good morning and welcome to Moderna's Conference Call. (Operator Instructions). Please be advised this call is being recorded.
At this time, I'd like to turn the call over to Lavina Talukdar, Head of Investor Relations at Moderna. Please proceed.
Thank you, operator. Good morning, everyone, and welcome. This morning, we issued a number of announcements that we'd like to discuss on the call with you today. You can access the 2 press releases and statements, as well as the slides that we'll be reviewing by going to the Investors section of our website.
On today's call are Stéphane Bancel, our Chief Executive Officer; Stephen Hoge, our President; Tal Zaks, our Chief Medical Officer; and David Meline, our Chief Financial Officer.
Before we begin, please note that this conference call will include forward-looking statements made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995.
Please see Slide 2 of the accompanying presentation and our
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |